Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.

Acta haematologica - 1 Jan 2013

Chang Hung, Shih Lee-Yung, Michelson Alan D, Dunn Po, Frelinger Andrew L, Wang Po-Nan, Kuo Ming-Chung, Lin Tung-Liang, Wu Jin-Hou, Tang Tzung-Chih

Abstract excerpt

BACKGROUND: Patients with myeloproliferative neoplasms (MPN) have an increased risk for thrombosis and bleeding and show a defect in adenosine diphosphate (ADP)-induced platelet aggregation. This risk of thrombosis is further increased in MPN patients bearing the JAK2V617F mutation. Two ADP receptors, P2Y1 and P2Y12, are present on platelets. Although the pattern of defective ADP-induced platelet aggregation in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Platelets
Share to Hematologic Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hemorrhage

Share to Leukocyte Count

Share to Myeloproliferative Disorders

Share to Platelet Function Tests

Share to Receptors, Purinergic P2Y12

Share to Thrombosis

Source

Identifiers

PMID: 23751441
DOI: 10.1159/000348413

Genes

VASP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.PMID 23751441Read ↗

Increased bleeding and thrombosis in myeloproliferative neoplasms mediated through altered expression of inherited platelet disorder genesSemantic proximity Read ↗

Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Platelet Heterogeneity in Myeloproliferative Neoplasms.Semantic proximity Read ↗

Platelet proteo-transcriptomic profiling validates mediators of thrombosis and proteostasis in patients with myeloproliferative neoplasmsSemantic proximity Read ↗

JAK2 mutation and thrombosis in the myeloproliferative neoplasms.Semantic proximity Read ↗

JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.Semantic proximity Read ↗

Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms.Semantic proximity Read ↗

Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutationSemantic proximity Read ↗

Vascular Endothelial Dysfunction in Myeloproliferative Neoplasms and Gene Mutations.Semantic proximity Read ↗

Novel hematological parameters for the evaluation of patients with myeloproliferative neoplasms: the immature platelet and reticulocyte fractions.Semantic proximity Read ↗

Platelet Dysfunction and Thrombosis in JAK2V617F-Mutated Primary Myelofibrotic Mice.Semantic proximity Read ↗

Circulating Protein Disulfide Isomerase Is Associated with Increased Risk of Thrombosis in JAK2-Mutated Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.